Published in Pharmacoeconomics on October 01, 2013
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med (2014) 0.99
Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? Eur J Health Econ (2015) 0.86
Value of Treating All Stages of Chronic Hepatitis C: A Comprehensive Review of Clinical and Economic Evidence. Infect Dis Ther (2016) 0.79
Rethinking cost-effectiveness in the era of zero healthcare spending growth. Int J Equity Health (2016) 0.75
An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal. BMC Res Notes (2016) 0.75
Primary Care-Based Hepatitis C Treatment Outcomes With First-Generation Direct-Acting Agents. J Addict Med (2015) 0.75
[Cost and mortality associated to the surgical delay of patients with a hip fracture. Spain]. Rev Esp Salud Publica (2014) 1.47
Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Making (2012) 1.22
Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ (2010) 1.17
[A proposed guideline for economic evaluation of health technologies]. Gac Sanit (2009) 1.05
Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol (2005) 1.05
Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--4. Value Health (2012) 1.05
Discrete-event simulation applied to analysis of waiting lists. Evaluation of a prioritization system for cataract surgery. Value Health (2008) 0.84
Validation of the Spanish translation of the questionnaire for the obesity-related problems scale. Obes Surg (2009) 0.84
[Effectiveness of pre-operative education in reducing anxiety in surgical patients]. Enferm Clin (2011) 0.82
Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy. Int J Clin Pharm (2012) 0.80
Geographical variations in the benefit of applying a prioritization system for cataract surgery in different regions of Spain. BMC Health Serv Res (2008) 0.79
[Cost of breast cancer treatment by clinical stage in the Basque Country, Spain]. Rev Esp Salud Publica (2015) 0.79
Cost-utility analysis of gastric bypass for severely obese patients in Spain. Obes Surg (2014) 0.78
The "flying saucer" sign on spectral domain optical coherence tomography in chloroquine retinopathy. Arthritis Rheum (2013) 0.77
Measuring health-related quality of life in drug clinical trials: is it given due importance? Pharm World Sci (2007) 0.77
An assessment of existing models for individualized breast cancer risk estimation in a screening program in Spain. BMC Cancer (2013) 0.77
[Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain]. Rev Neurol (2010) 0.75
Is the incidence of hip fractures becoming lower? Reumatol Clin (2013) 0.75
[Mathematical models for economic evaluation: dynamic models based on differential equations]. Gac Sanit (2009) 0.75
Cost-effectiveness of protease inhibitor based regimens for chronic hepatitis C: a systematic review of published literature. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75
Reliability of portal control procedure in irradiation of breast cancer: a Bayesian analysis. Radiother Oncol (2005) 0.75